Commonwealth Equity Services
GTBP icon

Commonwealth Equity Services’s GT Biopharma GTBP Stock Holding History

Commonwealth Equity Services’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-337
Closed -$3K – 4049
2023
Q4 		$3K Hold
337
– – ﹤0.01% 3890
2023
Q3 		$2K Hold
337
– – ﹤0.01% 3817
2023
Q2 		$3K Hold
337
– – ﹤0.01% 3820
2023
Q1 		$5 Buy
+337
New +$7.72K ﹤0.01% 3748
2022
Q4 		– Sell
-372
Closed -$19K – 3743
2022
Q3 		$19K Hold
372
– – ﹤0.01% 3586
2022
Q2 		$33K Hold
372
– – ﹤0.01% 3532
2022
Q1 		$32K Buy
372
+4
+1% +$353 ﹤0.01% 3623
2021
Q4 		$33K Buy
+368
New +$55.1K ﹤0.01% 3570

Other funds holding GTBP

Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Commonwealth Equity Services's GTBP Position: Q1 2024 in Review

Commonwealth Equity Services sold out of GT Biopharma (GTBP) in Q1 2024, closing a stake of 337 shares — an estimated $3K sold.

Commonwealth Equity Services first reported a position in GTBP in Q4 2021 and held it in 8 quarters. The position peaked at $33K in Q2 2022. 17 funds tracked by Wall St. Rank hold GTBP as of Q1 2024.

  • Commonwealth Equity Services reported no remaining GT Biopharma position as of Q1 2024 after selling out during the quarter.
  • Commonwealth Equity Services sold 337 GT Biopharma shares in Q1 2024, an estimated $3K.
  • Commonwealth Equity Services first reported a position in GT Biopharma in Q4 2021 and held it in 8 quarters.
  • Commonwealth Equity Services's GT Biopharma position peaked at $33K in Q2 2022.
  • 17 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2024.

Based on Commonwealth Equity Services's 13F filing for Q1 2024, filed 29 Apr 2024.